# A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

> **NCT00605384** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 4 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Entecavir + Tenofovir
- **DRUG:** Adefovir + continuing Lamivudine

## Key facts

- **NCT ID:** NCT00605384
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business Objectives Have Changed
- **Last updated:** 2010-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605384, "A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00605384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*